ASX : EMD Delivering the new paradigm in mental health care 2026 Annual General Meeting Presentation November 2026 1 Advanced therapies. Compassionate care. Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial...
2026 Annual General Meeting Presentation
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The company reported a substantial increase in revenue compared to the previous year, driven by the expansion of its clinic network. Emyria is focusing on leveraging momentum in psychedelic drug treatments and has appointed a strategic advisor to enhance its US opportunities. The presentation outlines recent achievements and future drivers for growth, emphasizing the company's commitment to shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Story so far
Earlier from Emyria
- Notification of cessation of securities - EMD
- September 2026 Quarterly Investor Webinar Presentation
- September 2026 Quarterly Investor Update Webinar Invitation
- September 2026 Quarterly Activities Report and Appendix 4C
- Annual Report
Later from Emyria
- Results of Annual General Meeting
- Final Director's Interest Notice - J. Tooke
- Application for quotation of securities - EMD
- Change of Director's Interest Notice x 2
- Emyria Recruits 31 Therapists to Meet Growing Patient Demand
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria